Logo image of SGMO

SANGAMO THERAPEUTICS INC (SGMO) Stock Fundamental Analysis

USA - NASDAQ:SGMO - US8006771062 - Common Stock

0.4999 USD
-0.01 (-0.99%)
Last: 9/15/2025, 12:35:54 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SGMO. SGMO was compared to 540 industry peers in the Biotechnology industry. While SGMO seems to be doing ok healthwise, there are quite some concerns on its profitability. SGMO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SGMO has reported negative net income.
In the past year SGMO has reported a negative cash flow from operations.
In the past 5 years SGMO always reported negative net income.
SGMO had negative operating cash flow in 4 of the past 5 years.
SGMO Yearly Net Income VS EBIT VS OCF VS FCFSGMO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

The Return On Assets of SGMO (-66.21%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -329.53%, SGMO is doing worse than 72.78% of the companies in the same industry.
Industry RankSector Rank
ROA -66.21%
ROE -329.53%
ROIC N/A
ROA(3y)-95.5%
ROA(5y)-64.82%
ROE(3y)-268.79%
ROE(5y)-175.64%
ROIC(3y)N/A
ROIC(5y)N/A
SGMO Yearly ROA, ROE, ROICSGMO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

SGMO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SGMO Yearly Profit, Operating, Gross MarginsSGMO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

More info and screens

5

2. Health

2.1 Basic Checks

SGMO does not have a ROIC to compare to the WACC, probably because it is not profitable.
SGMO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SGMO has more shares outstanding
SGMO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SGMO Yearly Shares OutstandingSGMO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
SGMO Yearly Total Debt VS Total AssetsSGMO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -22.40, we must say that SGMO is in the distress zone and has some risk of bankruptcy.
SGMO's Altman-Z score of -22.40 is on the low side compared to the rest of the industry. SGMO is outperformed by 85.74% of its industry peers.
There is no outstanding debt for SGMO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -22.4
ROIC/WACCN/A
WACC9.59%
SGMO Yearly LT Debt VS Equity VS FCFSGMO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

SGMO has a Current Ratio of 1.05. This is a normal value and indicates that SGMO is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of SGMO (1.05) is worse than 86.48% of its industry peers.
A Quick Ratio of 1.05 indicates that SGMO should not have too much problems paying its short term obligations.
The Quick ratio of SGMO (1.05) is worse than 85.93% of its industry peers.
Industry RankSector Rank
Current Ratio 1.05
Quick Ratio 1.05
SGMO Yearly Current Assets VS Current LiabilitesSGMO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 78.99% over the past year.
The Revenue has grown by 540.33% in the past year. This is a very strong growth!
Measured over the past years, SGMO shows a very negative growth in Revenue. The Revenue has been decreasing by -10.81% on average per year.
EPS 1Y (TTM)78.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.56%
Revenue 1Y (TTM)540.33%
Revenue growth 3Y-19.48%
Revenue growth 5Y-10.81%
Sales Q2Q%5042.13%

3.2 Future

The Earnings Per Share is expected to grow by 23.07% on average over the next years. This is a very strong growth
SGMO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 38.32% yearly.
EPS Next Y41.91%
EPS Next 2Y17.92%
EPS Next 3Y18.19%
EPS Next 5Y23.07%
Revenue Next Year20.34%
Revenue Next 2Y-0.51%
Revenue Next 3Y25.09%
Revenue Next 5Y38.32%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SGMO Yearly Revenue VS EstimatesSGMO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
SGMO Yearly EPS VS EstimatesSGMO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SGMO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SGMO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SGMO Price Earnings VS Forward Price EarningsSGMO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SGMO Per share dataSGMO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2 -0.3

4.3 Compensation for Growth

SGMO's earnings are expected to grow with 18.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.92%
EPS Next 3Y18.19%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SGMO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SANGAMO THERAPEUTICS INC

NASDAQ:SGMO (9/15/2025, 12:35:54 PM)

0.4999

-0.01 (-0.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-10 2025-11-10/amc
Inst Owners22.94%
Inst Owner Change-4.05%
Ins Owners1.4%
Ins Owner Change-3.04%
Market Cap150.82M
Analysts80
Price Target4.18 (736.17%)
Short Float %5.41%
Short Ratio2.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)16.72%
Min EPS beat(2)-5.04%
Max EPS beat(2)38.49%
EPS beat(4)2
Avg EPS beat(4)63.13%
Min EPS beat(4)-18.18%
Max EPS beat(4)237.26%
EPS beat(8)2
Avg EPS beat(8)12.09%
EPS beat(12)5
Avg EPS beat(12)13.56%
EPS beat(16)9
Avg EPS beat(16)13.61%
Revenue beat(2)0
Avg Revenue beat(2)-29.13%
Min Revenue beat(2)-43.35%
Max Revenue beat(2)-14.91%
Revenue beat(4)1
Avg Revenue beat(4)16.52%
Min Revenue beat(4)-45.63%
Max Revenue beat(4)169.98%
Revenue beat(8)1
Avg Revenue beat(8)-26.17%
Revenue beat(12)2
Avg Revenue beat(12)22.97%
Revenue beat(16)6
Avg Revenue beat(16)19.23%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)100.69%
EPS NQ rev (3m)100.15%
EPS NY rev (1m)18.41%
EPS NY rev (3m)36.99%
Revenue NQ rev (1m)437.5%
Revenue NQ rev (3m)489.71%
Revenue NY rev (1m)26.83%
Revenue NY rev (3m)35.39%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.85
P/FCF N/A
P/OCF N/A
P/B 7.69
P/tB 7.69
EV/EBITDA N/A
EPS(TTM)-0.29
EYN/A
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)-0.12
FCFYN/A
OCF(TTM)-0.12
OCFYN/A
SpS0.27
BVpS0.06
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -66.21%
ROE -329.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-95.5%
ROA(5y)-64.82%
ROE(3y)-268.79%
ROE(5y)-175.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.84
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.51%
Cap/Sales 0.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.05
Quick Ratio 1.05
Altman-Z -22.4
F-Score6
WACC9.59%
ROIC/WACCN/A
Cap/Depr(3y)104.2%
Cap/Depr(5y)163.67%
Cap/Sales(3y)10.21%
Cap/Sales(5y)12.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.56%
EPS Next Y41.91%
EPS Next 2Y17.92%
EPS Next 3Y18.19%
EPS Next 5Y23.07%
Revenue 1Y (TTM)540.33%
Revenue growth 3Y-19.48%
Revenue growth 5Y-10.81%
Sales Q2Q%5042.13%
Revenue Next Year20.34%
Revenue Next 2Y-0.51%
Revenue Next 3Y25.09%
Revenue Next 5Y38.32%
EBIT growth 1Y73.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.78%
EBIT Next 3Y10.27%
EBIT Next 5Y29.52%
FCF growth 1Y86.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y84.89%
OCF growth 3YN/A
OCF growth 5YN/A